The Lancet HIV
| 短名 | Lancet. HIV. |
| Journal Impact | 12.66 |
| 国际分区 | INFECTIOUS DISEASES(Q1) |
| 期刊索引 | SCI Q1中科院 1 区 |
| ISSN | 2352-3018, 2405-4704 |
| h-index | 81 |
| 国内分区 | 医学(1区)医学免疫学(1区)医学传染病学(1区) |
| Top期刊 | 是 |
LANCET HIV 于 2014 年 9 月作为独家在线期刊推出，发表原创研究、专家评论、信息丰富的社论和及时的通信。该月刊为读者提供了有关影响当今 HIV/AIDS 研究的临床进展和改变实践的研究的背景和见解。现在是抗击 HIV/AIDS 的关键时刻。尽管世界认为艾滋病的终结可能触手可及，但控制这种流行病的工作肯定还没有完成。随着艾滋病毒疾病演变为慢性感染，病毒与其他慢性病的相互作用将带来许多新的挑战。 THE LANCET HIV 是一本面向 HIV/AIDS 历史新纪元的期刊。LANCET HIV 建立在 THE LANCET 期刊以发表 HIV/AIDS 研究的声誉之上，为宣传以及计划和政治变革提供了可靠的基础。我们将考虑临床、流行病学、操作和实施研究，将这些学科统一到一个单一的愿景中，以促进 HIV 感染者的健康。
期刊主页投稿网址| 涉及主题 | 医学生物家庭医学病毒学免疫学人类免疫缺陷病毒（HIV）政治学法学化学生物化学病理内科学梅德林遗传学社会学病毒病毒载量环境卫生计算机科学心理学 |
| 出版信息 | 出版商: Elsevier Ltd，出版周期: ，期刊类型: journal |
| 基本数据 | 创刊年份: 2014，原创研究文献占比: 75.81%，自引率:4.70%， Gold OA占比: 37.00% |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Antiretroviral efficacy versus neurotoxicity
2024-9-1
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort
2024-9-1
Correction to Lancet HIV 2024; 11: e233–44
2024-9-1
Preventing sexually transmitted infections in the age of PrEP
2024-9-1
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study
2024-9-1
Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study
2024-9-1
Where does doravirine fit in current antiretroviral therapy?
2024-9-1
GHESKIO's model of patient care during civil unrest in Haiti
2024-9-1
Highlights from the 25th International AIDS Conference
2024-9-1
Incentivising engagement in care among people with HIV
2024-9-1
Optimising anal cancer screening through risk stratification
2024-9-1
Optimising HIV spending in eastern Europe and central Asia
2024-9-1
Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study
2024-9-1
Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study
2024-8-27
A game-changer for PrEP if access is adequate
2024-8-27
Complex response to HIV and tuberculosis in South Sudan
2024-8-1
Correction to Lancet HIV 2024; published online Aug 16. https://doi.org/10.1016/S2352-3018(24)00173-5
2024-8-1
The long wait for long-acting HIV prevention and treatment formulations
2024-8-1
Impact of a point-of-care urine tenofovir assay on adherence to HIV pre-exposure prophylaxis among women in Kenya: a randomised pilot trial
2024-8-1
US funding for HIV at risk again
2024-8-1
Untangling the causal ties between antiretrovirals and obesity
2024-8-1
All roads lead to Westminster: the infected blood scandal
2024-8-1
Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness–implementation trial
2024-8-1
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration
2024-8-1
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis
2024-7-1
Low-cost point-of-care urine test to enhance PrEP adherence
2024-7-1
Person-centred care for older adults living with HIV in sub-Saharan Africa
2024-7-1
Effects of self-testing on HIV outcomes in west Africa
2024-7-1
Madagascar urgently needs a 2024 national prevalence survey of HIV
2024-7-1
IAPAC–Lancet HIV Commission on the future of urban HIV responses
2024-7-1
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation
2024-7-1
Reducing HIV transmission in British Columbia, Canada
2024-7-1
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium
2024-7-1
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries
2024-7-1
Addressing partner violence to end infant HIV infection
2024-7-1
Second-line HIV treatments for adults in LMICs
2024-7-1
Steatotic liver disease and HIV: an agenda for 2030
2024-7-1
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
2024-7-1
Novel anti-obesity drugs for people with HIV
2024-7-1
Creativity until you drop dead
2024-7-1
Is HIV epidemic control by 2030 realistic?
2024-7-1
Integration of sexual health and HIV services
2024-7-1
Reassuring long-term safety, resistance, and efficacy data for two daily formulations of PrEP
2024-7-1
Effectiveness of integrating HIV prevention within sexual reproductive health services with or without peer support among adolescents and young adults in rural KwaZulu-Natal, South Africa (Isisekelo Sempilo): 2 × 2 factorial, open-label, randomised controlled trial
2024-6-24
UK Infected Blood Inquiry highlights decades of failings
2024-6-13
Long-overdue conclusion to the UK Infected Blood Inquiry
2024-6-13
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa
2024-6-6
Recent gay Black history in the UK
2024-6-1
Mandala: helping combat HIV in Georgia
2024-6-1
Legislation threat to services for LGBTQ+ people in Georgia
2024-6-1
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远